Skip to content

Study · Not a test of the peptide alone · 2008

6 results

[Expression and activity analysis of interferonalpha-con and thymosin-alpha1].

Liu X, Liu F, Li B, Zhou H, Wang Q

Sheng wu gong cheng xue bao = Chinese journal of biotechnology1 Jul 2008Cited by 1 (Europe PMC)

PMID18837390 (opens in a new tab)PepBankPUB-18837390
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In a cytopathic-effect inhibition assay, the thymosin alpha1 and consensus IFN-alpha fusion protein had higher antiviral activity than commercial IFNalpha1b and IFNalpha2a.

    In plain wordsIn lab tests, a fusion protein that includes thymosin alpha1 had stronger antiviral activity than commercial interferon products.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseAntiviral activity of fusion protein
    Study

    n: not reported in source

    Comparator
    Commercial IFNalpha1b and IFNalpha2a
    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    The activity for antivirus was higher than commercial IFNalpha1b and IFNalpha2a
    1 context sentence
    Summary · context
    The activity of fusion protein for antivirus was tested by cytopathic-effect inhibition assay

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In a cell proliferation assay, the thymosin alpha1 and consensus IFN-alpha fusion protein promoted lymphocyte proliferation similarly to commercial TM-alpha1.

    In plain wordsIn lab tests, a fusion protein that includes thymosin alpha1 promoted lymphocyte growth about as well as commercial thymosin alpha1.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLymphocyte proliferation activity of fusion protein
    Study

    n: not reported in source

    Comparator
    Commercial TM-alpha1
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    activity for promoting lymphocyte proliferation was similar to commercial TM-alpha1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In vitro, the thymosin alpha1 and consensus IFN-alpha fusion protein had a stronger anti-HBV effect than the combination of IFNalpha and TM-alpha1.

    In plain wordsIn lab tests, a fusion protein that includes thymosin alpha1 worked better against hepatitis B virus than the two drugs given together.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseAnti-HBV effect in vitro versus IFNalpha plus TM-alpha1
    Study

    n: not reported in source

    Comparator
    Combination of IFNalpha and TM-alpha1
    Outcome group
    Antiviral activity · Infection

    Source sentences

    Summary
    The fusion protein had better effect for anti-HBV in vitro, its effect was stronger than combination of IFNalpha and TM-alpha1 and

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Safety outcome

    In vitro, the thymosin alpha1 and consensus IFN-alpha fusion protein had less cell toxicity than the combination of IFNalpha and TM-alpha1.

    In plain wordsIn lab tests, a fusion protein that includes thymosin alpha1 was less toxic to cells than the two drugs given together.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCell toxicity versus IFNalpha plus TM-alpha1
    Study

    n: not reported in source

    Comparator
    Combination of IFNalpha and TM-alpha1
    Outcome group
    Adverse events · Pharmacology

    Source sentences

    Summary
    cell toxicity was less than combination of IFNalpha and TM-alpha1.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05LabNot a test of Thymosin alpha-1 aloneOther designOther

    A soluble thymosin alpha1 and consensus IFN-alpha fusion protein made up more than 20% of total protein in E. coli.

    In plain wordsIn bacteria, a fusion protein that includes thymosin alpha1 was made in soluble form.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableExpression of fusion protein in E. coli
    Study

    Escherichia colin: not reported in source

    E. coli BL21 (DE3)-Codon plus-RP-X
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The expressed product (TM-alpha1-IFN-con) was soluble, and amounted to more than 20% in total proteins of E. coli.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06LabNot a test of Thymosin alpha-1 aloneOther designOther

    A multi-step purification gave the thymosin alpha1 and consensus IFN-alpha fusion protein at more than 96% purity.

    In plain wordsIn the lab, a fusion protein that includes thymosin alpha1 was purified to high purity.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicablePurity of fusion protein
    Study

    Escherichia colin: not reported in source

    E. coli BL21 (DE3)-Codon plus-RP-X
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    By precipitation of (NH4)2SO4, hydrophobic interaction chromatography (HIC, Phenyl Sepharose 6 Fast Flow), anion-exchange chromatography (Q Sepharose Fast Flow), cation-exchange chromatography (SP Sepharose Fast Flow) and gel filtration (Sephadex G-75), it was purified to more than 96% purity.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.